How can a company with a truly great product turn into a zombie public company on life support?
Today I am going to highlight Integrum.
This is an easy one to understand because they are publicly traded and we can watch the train wreck in slow motion.
Website - https://www.integrum.us/
In ortho, we are conditioned to believe that "Product is King." We spend years in R&D labs, navigate the grueling PMA or 510(k) pathways, and fight for every inch of clinical validation. We assume that if the technology is paradigm-shifting—if it truly solves a problem for the patient and the surgeon—the financial success is a foregone conclusion.
But the industry is littered with the ghosts of "great products" that became "zombie companies." These are the public entities that possess FDA-cleared, clinically superior tech but are currently wandering the halls of the NASDAQ or Spotlight markets on life support, their valuations gutted and their cash runways measured in weeks, not years.
A prime, sobering example currently playing out in the public markets is Integrum AB.
The Asset: A Clinical Masterpiece
Integrum’s OPRA™ Implant System for osseointegration is, by all accounts, a masterpiece.
I...
